we replaced the MDD diagnosis from MVP with the SR-Depression GWAS for a total of 1,114,383 participants. For the secondary analysis of depressive symptoms by PHQ, we included 286,821 total participants from UKB and MVP. We also performed a GWAS in the MVP African American (AA) sample of 59,600 participants. We included these participants in a transancestral meta-analysis with a total sample size of 1,213,867 participants (Figure S5). Cohorts are detailed in Table 1. All data were collected independently and therefore the analysts were blinded to the conditions of the analysis. No randomization was performed. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications. 8,10
